Former Blueprint vets take their new biotech out of stealth, with STAT3 in their sights

A new biotech going after STAT mutations through a previously undruggable target emerged from stealth and secured its first fundraise Monday, introducing its freshly minted CEO in the process.

Recludix Pharma, a San Diego biotech launched by a founding team of Blueprint Medicines vets, pulled in a $60 million Series...

Click to view original post